A5103096255- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Reproductive Health and Contraception
- Cancer survivorship and care
- Palliative Care and End-of-Life Issues
- Cancer Risks and Factors
- Uterine Myomas and Treatments
- Endometriosis Research and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Childhood Cancer Survivors' Quality of Life
- HER2/EGFR in Cancer Research
- Sarcoma Diagnosis and Treatment
- Blood Coagulation and Thrombosis Mechanisms
- Lung Cancer Treatments and Mutations
- Venous Thromboembolism Diagnosis and Management
- Renal cell carcinoma treatment
- Cancer Mechanisms and Therapy
- Chromatin Remodeling and Cancer
- BRCA gene mutations in cancer
- Molecular Biology Techniques and Applications
- Cancer-related molecular mechanisms research
- Cervical Cancer and HPV Research
- Estrogen and related hormone effects
- Pelvic floor disorders treatments
- Neutropenia and Cancer Infections
Walter Reed National Military Medical Center
2014-2022
Uniformed Services University of the Health Sciences
2022
Johns Hopkins University
2018
University of Arkansas for Medical Sciences
2018
University of Maryland, Baltimore
2018
Greater Baltimore Medical Center
2018
Duke Medical Center
2011-2014
Duke University
2011-2014
Inova Health System
2014
University of North Carolina at Chapel Hill
2012-2013
Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, overexpressed in 30% uterine carcinoma. This multicenter, randomized phase II trial compared carboplatin-paclitaxel with and without trastuzumab patients advanced or recurrent who overexpress HER2/neu. Methods Eligible had primary stage III IV HER2/neu-positive disease. Participants were randomly...
Abstract Purpose: Uterine-serous-carcinoma (USC) is an aggressive variant of endometrial cancer. On the basis preliminary results a multicenter, randomized phase II trial, trastuzumab (T), humanized-mAb targeting Her2/Neu, in combination with carboplatin/paclitaxel (C/P), recognized as alternative treating advanced/recurrent HER2/Neu-positive USC. We report updated survival analysis NCT01367002. Patients and Methods: Eligible patients had stage III to IV or recurrent disease. Participants...
Inactivating somatic mutations in the ARID1A gene are described a significant fraction of clear cell and endometrioid ovarian cancers leading to loss corresponding protein (BAF250a). Expression BAF250a was examined accrued as part North Carolina Ovarian Cancer Study, population-based case-control study, determine whether expression is associated with clinical epidemiological features.Immunostaining for performed using 212 cancers. Associations between features were examined. Variables...
•Uterine morcellation is common in minimally invasive hysterectomy but should be performed with caution due to risk of unsuspected malignancy.•Intraoperative techniques considered minimize dissemination endometrial tissue during morcellation.•Strategies ensure accurate pathologic evaluation morcellated specimens and improve preoperative stratification before procedures are necessary.